Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

Semaglutide is a glucagon-like peptide-1 analogue in development for the treatment of type 2 diabetes.

Its effects on first- and second-phase insulin secretion and other measures of beta cell function and glycaemic control were assessed.

Who Took Part

PubMed indexes the participants as teenagers, young adults, adults and middle-aged adults, women only.

Co-primary endpoints were changes from baseline to end of treatment in the first (AUC0-10 min) and second (AUC10-120 min) insulin secretion phases, as measured by the IVGTT.

A graded glucose infusion test (GGIT) assessed insulin secretion rate (ISR) in treated participants and a group of untreated healthy participants.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and parallel-group.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.

Groups ran in parallel: each of the participants stayed in one arm throughout.

An arginine stimulation test (AST) and a 24 h meal stimulation test were also conducted.

Safety endpoints were also assessed.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin, Hypoglycemic Agents, Insulin-Secreting Cells and Metformin.

The authors tagged it with the keywords Beta cell function, Glycaemic control, Placebo-controlled trial, Semaglutide and Type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Diabetologia), a journal based in Germany.

More context: the Semaglutide compound page.